25 XP   0   0   10

Boryung Pharm
Buy, Hold or Sell?

Let's analyse Boryung together

PenkeI guess you are interested in Boryung Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Boryung Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Boryung Pharm

I send you an email if I find something interesting about Boryung Pharm.

Quick analysis of Boryung (30 sec.)










What can you expect buying and holding a share of Boryung? (30 sec.)

How much money do you get?

How much money do you get?
₩0.14
When do you have the money?
1 year
How often do you get paid?
85.7%

What is your share worth?

Current worth
₩8,338.98
Expected worth in 1 year
₩8,839.89
How sure are you?
96.4%

+ What do you gain per year?

Total Gains per Share
₩700.91
Return On Investment
6.4%

For what price can you sell your share?

Current Price per Share
₩10,950.00
Expected price per share
₩10,800 - ₩13,750
How sure are you?
50%

1. Valuation of Boryung (5 min.)




Live pricePrice per Share (EOD)

₩10,950.00

Intrinsic Value Per Share

₩5,089.27 - ₩6,295.89

Total Value Per Share

₩13,428.25 - ₩14,634.86

2. Growth of Boryung (5 min.)




Is Boryung growing?

Current yearPrevious yearGrowGrow %
How rich?$384.4m$351.5m$24.9m6.6%

How much money is Boryung making?

Current yearPrevious yearGrowGrow %
Making money$7m$7.3m-$296k-4.2%
Net Profit Margin4.7%5.6%--

How much money comes from the company's main activities?

3. Financial Health of Boryung (5 min.)




What can you expect buying and holding a share of Boryung? (5 min.)

Welcome investor! Boryung's management wants to use your money to grow the business. In return you get a share of Boryung.

What can you expect buying and holding a share of Boryung?

First you should know what it really means to hold a share of Boryung. And how you can make/lose money.

Speculation

The Price per Share of Boryung is ₩10,950. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Boryung.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Boryung, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩8,338.98. Based on the TTM, the Book Value Change Per Share is ₩125.23 per quarter. Based on the YOY, the Book Value Change Per Share is ₩165.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩50.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Boryung.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.060.0%0.110.0%0.110.0%0.100.0%0.080.0%
Usd Book Value Change Per Share0.030.0%0.090.0%0.120.0%0.160.0%0.210.0%
Usd Dividend Per Share0.000.0%0.040.0%0.070.0%0.040.0%0.040.0%
Usd Total Gains Per Share0.030.0%0.120.0%0.190.0%0.200.0%0.250.0%
Usd Price Per Share8.32-6.81-7.50-9.55-13.72-
Price to Earnings Ratio34.99-18.37-3.71-16.10-98.05-
Price-to-Total Gains Ratio290.96-104.71-62.32-137.30-172.28-
Price to Book Ratio1.43-1.19-1.41-2.41-8.04-
Price-to-Total Gains Ratio290.96-104.71-62.32-137.30-172.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.665
Number of shares130
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.04
Usd Book Value Change Per Share0.090.16
Usd Total Gains Per Share0.120.20
Gains per Quarter (130 shares)15.9526.06
Gains per Year (130 shares)63.78104.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1184654238194
2369111846162198
35513718270243302
47318224693324406
591228310116405510
6109273374139486614
7127319438163567718
8146365502186648822
9164410566209729926
101824566302328101030

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%18.02.00.090.0%26.02.00.092.9%26.02.00.092.9%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%24.04.00.085.7%24.04.00.085.7%
Dividend per Share2.00.02.050.0%10.00.02.083.3%16.00.04.080.0%24.00.04.085.7%24.00.04.085.7%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%27.01.00.096.4%27.01.00.096.4%

Fundamentals of Boryung

About Boryung Pharm

Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, diabetes, central nervous system, and oncology drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 20:54:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Boryung Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Boryung earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 2.4% means that ₩0.02 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Boryung Pharm:

  • The MRQ is 2.4%. The company is making a profit. +1
  • The TTM is 4.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.4%TTM4.7%-2.3%
TTM4.7%YOY5.6%-0.9%
TTM4.7%5Y5.6%-0.9%
5Y5.6%10Y6.8%-1.1%
1.1.2. Return on Assets

Shows how efficient Boryung is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.6% Return on Assets means that Boryung generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Boryung Pharm:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.1%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM1.1%-0.5%
TTM1.1%YOY1.2%-0.1%
TTM1.1%5Y1.3%-0.2%
5Y1.3%10Y1.6%-0.3%
1.1.3. Return on Equity

Shows how efficient Boryung is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.0% Return on Equity means Boryung generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Boryung Pharm:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.9%-0.9%
TTM1.9%YOY2.1%-0.2%
TTM1.9%5Y2.3%-0.4%
5Y2.3%10Y2.8%-0.5%

1.2. Operating Efficiency of Boryung Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Boryung is operating .

  • Measures how much profit Boryung makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Boryung Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.2%-2.2%
TTM2.2%YOY7.5%-5.3%
TTM2.2%5Y7.5%-5.3%
5Y7.5%10Y6.1%+1.3%
1.2.2. Operating Ratio

Measures how efficient Boryung is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are ₩1.49 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Boryung Pharm:

  • The MRQ is 1.492. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.351. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.492TTM1.351+0.140
TTM1.351YOY1.361-0.010
TTM1.3515Y1.448-0.096
5Y1.44810Y1.477-0.030

1.3. Liquidity of Boryung Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Boryung is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.88 means the company has ₩1.88 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Boryung Pharm:

  • The MRQ is 1.878. The company is able to pay all its short-term debts. +1
  • The TTM is 1.743. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.878TTM1.743+0.136
TTM1.743YOY1.825-0.082
TTM1.7435Y2.038-0.295
5Y2.03810Y1.918+0.119
1.3.2. Quick Ratio

Measures if Boryung is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.80 means the company can pay off ₩0.80 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Boryung Pharm:

  • The MRQ is 0.795. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.769. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.795TTM0.769+0.026
TTM0.769YOY0.939-0.170
TTM0.7695Y0.987-0.218
5Y0.98710Y0.981+0.007

1.4. Solvency of Boryung Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Boryung assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Boryung to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.40 means that Boryung assets are financed with 40.0% credit (debt) and the remaining percentage (100% - 40.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Boryung Pharm:

  • The MRQ is 0.400. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.420. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.400TTM0.420-0.020
TTM0.420YOY0.431-0.011
TTM0.4205Y0.442-0.023
5Y0.44210Y0.445-0.003
1.4.2. Debt to Equity Ratio

Measures if Boryung is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 66.7% means that company has ₩0.67 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Boryung Pharm:

  • The MRQ is 0.667. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.726. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.667TTM0.726-0.059
TTM0.726YOY0.758-0.032
TTM0.7265Y0.798-0.072
5Y0.79810Y0.812-0.014

2. Market Valuation of Boryung Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Boryung generates.

  • Above 15 is considered overpriced but always compare Boryung to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 34.99 means the investor is paying ₩34.99 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Boryung Pharm:

  • The EOD is 32.220. Based on the earnings, the company is overpriced. -1
  • The MRQ is 34.986. Based on the earnings, the company is overpriced. -1
  • The TTM is 18.374. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD32.220MRQ34.986-2.766
MRQ34.986TTM18.374+16.611
TTM18.374YOY3.713+14.661
TTM18.3745Y16.100+2.275
5Y16.10010Y98.054-81.954
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Boryung Pharm:

  • The EOD is 49.205. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 53.429. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 17.291. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD49.205MRQ53.429-4.224
MRQ53.429TTM17.291+36.138
TTM17.291YOY-25.579+42.870
TTM17.2915Y9.573+7.718
5Y9.57310Y51.209-41.636
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Boryung is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.43 means the investor is paying ₩1.43 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Boryung Pharm:

  • The EOD is 1.313. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.426. Based on the equity, the company is underpriced. +1
  • The TTM is 1.189. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.313MRQ1.426-0.113
MRQ1.426TTM1.189+0.237
TTM1.189YOY1.413-0.224
TTM1.1895Y2.413-1.224
5Y2.41310Y8.037-5.624
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Boryung Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--40.865125.228-67%165.849-75%222.536-82%297.821-86%
Book Value Per Share--8338.9768165.146+2%7621.831+9%6233.987+34%5250.448+59%
Current Ratio--1.8781.743+8%1.825+3%2.038-8%1.918-2%
Debt To Asset Ratio--0.4000.420-5%0.431-7%0.442-10%0.445-10%
Debt To Equity Ratio--0.6670.726-8%0.758-12%0.798-16%0.812-18%
Dividend Per Share---50.000-100%99.985-100%63.873-100%56.066-100%
Eps--84.964152.594-44%158.966-47%139.759-39%116.605-27%
Free Cash Flow Per Share--55.63471.644-22%-354.444+737%-81.350+246%-114.069+305%
Free Cash Flow To Equity Per Share--55.634-515.042+1026%-410.029+837%-26.166+147%-15.418+128%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--6295.888--------
Intrinsic Value_10Y_min--5089.274--------
Intrinsic Value_1Y_max---227.347--------
Intrinsic Value_1Y_min---223.814--------
Intrinsic Value_3Y_max---29.007--------
Intrinsic Value_3Y_min---40.897--------
Intrinsic Value_5Y_max--957.891--------
Intrinsic Value_5Y_min--832.794--------
Market Cap721229415000.000-9%783143291900.000640708694025.000+22%705965382650.000+11%898570737924.962-13%2123421793495.705-63%
Net Profit Margin--0.0240.047-49%0.056-57%0.056-57%0.068-64%
Operating Margin---0.022-100%0.075-100%0.075-100%0.061-100%
Operating Ratio--1.4921.351+10%1.361+10%1.448+3%1.477+1%
Pb Ratio1.313-9%1.4261.189+20%1.413+1%2.413-41%8.037-82%
Pe Ratio32.220-9%34.98618.374+90%3.713+842%16.100+117%98.054-64%
Price Per Share10950.000-9%11890.0009727.500+22%10715.000+11%13635.999-13%19595.711-39%
Price To Free Cash Flow Ratio49.205-9%53.42917.291+209%-25.579+148%9.573+458%51.209+4%
Price To Total Gains Ratio267.953-9%290.955104.715+178%62.319+367%137.302+112%172.278+69%
Quick Ratio--0.7950.769+3%0.939-15%0.987-19%0.981-19%
Return On Assets--0.0060.011-44%0.012-48%0.013-53%0.016-62%
Return On Equity--0.0100.019-46%0.021-51%0.023-56%0.028-63%
Total Gains Per Share--40.865175.228-77%265.834-85%286.409-86%353.886-88%
Usd Book Value--384476813.287376462219.060+2%351518826.880+9%287570145.846+34%251531293.859+53%
Usd Book Value Change Per Share--0.0290.088-67%0.116-75%0.156-82%0.208-86%
Usd Book Value Per Share--5.8375.716+2%5.335+9%4.364+34%3.675+59%
Usd Dividend Per Share---0.035-100%0.070-100%0.045-100%0.039-100%
Usd Eps--0.0590.107-44%0.111-47%0.098-39%0.082-27%
Usd Free Cash Flow--2565064.2293303231.386-22%-16346975.610+737%-3755383.367+246%-6471734.623+352%
Usd Free Cash Flow Per Share--0.0390.050-22%-0.248+737%-0.057+246%-0.080+305%
Usd Free Cash Flow To Equity Per Share--0.039-0.361+1026%-0.287+837%-0.018+147%-0.011+128%
Usd Market Cap504860590.500-9%548200304.330448496085.818+22%494175767.855+11%628999516.547-13%1486395255.447-63%
Usd Price Per Share7.665-9%8.3236.809+22%7.501+11%9.545-13%13.717-39%
Usd Profit--3917332.7067035489.557-44%7331525.451-47%6447682.673-39%6530624.712-40%
Usd Revenue--161866065.963150434477.599+8%133083272.761+22%116673062.909+39%105415970.139+54%
Usd Total Gains Per Share--0.0290.123-77%0.186-85%0.200-86%0.248-88%
 EOD+4 -4MRQTTM+14 -21YOY+16 -195Y+14 -2110Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of Boryung Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1532.220
Price to Book Ratio (EOD)Between0-11.313
Net Profit Margin (MRQ)Greater than00.024
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.795
Current Ratio (MRQ)Greater than11.878
Debt to Asset Ratio (MRQ)Less than10.400
Debt to Equity Ratio (MRQ)Less than10.667
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.006
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Boryung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.069
Ma 20Greater thanMa 5011,625.000
Ma 50Greater thanMa 10012,218.800
Ma 100Greater thanMa 20011,832.400
OpenGreater thanClose10,880.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets915,511,541
Total Liabilities366,258,951
Total Stockholder Equity548,749,645
 As reported
Total Liabilities 366,258,951
Total Stockholder Equity+ 548,749,645
Total Assets = 915,511,541

Assets

Total Assets915,511,541
Total Current Assets377,659,485
Long-term Assets537,852,056
Total Current Assets
Cash And Cash Equivalents 16,460,520
Short-term Investments 3,594,152
Net Receivables 156,327,477
Inventory 189,805,874
Other Current Assets 4,421,091
Total Current Assets  (as reported)377,659,485
Total Current Assets  (calculated)370,609,115
+/- 7,050,370
Long-term Assets
Property Plant Equipment 211,774,861
Goodwill 3,696,121
Intangible Assets 169,172,907
Long-term Assets Other 0
Long-term Assets  (as reported)537,852,056
Long-term Assets  (calculated)384,643,889
+/- 153,208,167

Liabilities & Shareholders' Equity

Total Current Liabilities201,083,021
Long-term Liabilities165,175,929
Total Stockholder Equity548,749,645
Total Current Liabilities
Short Long Term Debt 50,610,858
Accounts payable 69,419,197
Other Current Liabilities 17,890,906
Total Current Liabilities  (as reported)201,083,021
Total Current Liabilities  (calculated)137,920,961
+/- 63,162,060
Long-term Liabilities
Long term Debt 151,708,150
Capital Lease Obligations Min Short Term Debt1,896,785
Long-term Liabilities Other 7,295,524
Long-term Liabilities  (as reported)165,175,929
Long-term Liabilities  (calculated)160,900,459
+/- 4,275,471
Total Stockholder Equity
Retained Earnings 406,936,348
Total Stockholder Equity (as reported)548,749,645
Total Stockholder Equity (calculated)406,936,348
+/- 141,813,297
Other
Capital Stock34,345,000
Common Stock Shares Outstanding 65,866
Net Debt 185,858,488
Net Invested Capital 751,068,653
Net Working Capital 176,576,463
Property Plant and Equipment Gross 378,070,401



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
421,747,189
396,827,477
428,648,837
402,516,283
405,833,780
410,128,402
453,429,027
450,017,573
481,658,501
490,539,115
507,867,161
507,628,914
494,446,731
628,280,995
683,741,065
647,993,966
670,620,579
682,134,841
807,730,928
828,641,139
857,380,519
866,546,375
911,771,794
892,385,915
952,571,382
903,571,650
937,604,613
915,511,541
915,511,541937,604,613903,571,650952,571,382892,385,915911,771,794866,546,375857,380,519828,641,139807,730,928682,134,841670,620,579647,993,966683,741,065628,280,995494,446,731507,628,914507,867,161490,539,115481,658,501450,017,573453,429,027410,128,402405,833,780402,516,283428,648,837396,827,477421,747,189
   > Total Current Assets 
261,388,270
230,635,371
249,172,603
228,539,114
229,802,563
227,981,400
245,785,706
224,545,928
218,012,964
217,133,869
228,453,507
231,851,317
220,473,596
344,033,653
349,833,009
315,660,225
326,700,221
339,631,256
455,337,801
437,313,716
449,331,064
462,423,284
509,331,252
338,378,355
401,636,280
355,355,213
391,153,522
377,659,485
377,659,485391,153,522355,355,213401,636,280338,378,355509,331,252462,423,284449,331,064437,313,716455,337,801339,631,256326,700,221315,660,225349,833,009344,033,653220,473,596231,851,317228,453,507217,133,869218,012,964224,545,928245,785,706227,981,400229,802,563228,539,114249,172,603230,635,371261,388,270
       Cash And Cash Equivalents 
50,786,284
16,431,963
13,247,482
16,376,925
14,460,949
12,372,551
9,751,016
7,617,713
2,114,233
2,540,720
5,688,772
4,522,869
1,995,522
69,721,063
109,421,376
25,526,945
42,576,825
40,788,501
158,323,078
150,708,196
126,308,326
10,966,479
35,112,513
16,072,987
18,072,286
15,316,324
12,633,714
16,460,520
16,460,52012,633,71415,316,32418,072,28616,072,98735,112,51310,966,479126,308,326150,708,196158,323,07840,788,50142,576,82525,526,945109,421,37669,721,0631,995,5224,522,8695,688,7722,540,7202,114,2337,617,7139,751,01612,372,55114,460,94916,376,92513,247,48216,431,96350,786,284
       Short-term Investments 
244,553
239,529
2,105,822
214,696
215,454
212,863
213,029
213,179
213,420
213,532
213,700
213,735
213,721
50,213,855
214,117
65,212,080
68,444,906
68,447,107
53,966,024
50,729,999
50,729,999
167,256,021
173,207,534
1,843,983
62,984,204
2,983,688
4,593,843
3,594,152
3,594,1524,593,8432,983,68862,984,2041,843,983173,207,534167,256,02150,729,99950,729,99953,966,02468,447,10768,444,90665,212,080214,11750,213,855213,721213,735213,700213,532213,420213,179213,029212,863215,454214,6962,105,822239,529244,553
       Net Receivables 
129,076,396
138,049,810
158,764,781
142,985,114
141,430,881
135,466,933
142,846,350
130,188,281
121,071,751
121,745,849
127,970,653
132,081,586
123,067,750
115,796,479
125,116,911
113,580,102
104,276,981
104,708,005
108,725,602
116,804,622
126,037,715
129,686,098
136,723,987
143,853,360
137,483,814
152,782,767
156,457,692
156,327,477
156,327,477156,457,692152,782,767137,483,814143,853,360136,723,987129,686,098126,037,715116,804,622108,725,602104,708,005104,276,981113,580,102125,116,911115,796,479123,067,750132,081,586127,970,653121,745,849121,071,751130,188,281142,846,350135,466,933141,430,881142,985,114158,764,781138,049,810129,076,396
       Inventory 
77,001,822
72,756,095
72,156,444
60,720,875
66,051,086
70,467,698
83,071,862
75,829,816
78,005,340
76,002,114
79,835,855
85,057,652
86,922,117
98,337,908
101,719,386
95,492,292
102,325,353
115,321,157
118,235,495
110,994,217
134,676,800
138,815,729
148,141,134
164,621,337
166,748,093
172,715,460
199,196,269
189,805,874
189,805,874199,196,269172,715,460166,748,093164,621,337148,141,134138,815,729134,676,800110,994,217118,235,495115,321,157102,325,35395,492,292101,719,38698,337,90886,922,11785,057,65279,835,85576,002,11478,005,34075,829,81683,071,86270,467,69866,051,08660,720,87572,156,44472,756,09577,001,822
   > Long-term Assets 
0
0
0
0
0
0
0
0
263,645,537
273,405,246
279,413,654
275,777,597
273,973,135
284,247,342
333,908,056
332,333,742
343,920,358
342,503,584
352,393,127
391,327,423
408,049,455
404,123,091
402,440,542
554,007,560
550,935,102
548,216,437
546,451,091
537,852,056
537,852,056546,451,091548,216,437550,935,102554,007,560402,440,542404,123,091408,049,455391,327,423352,393,127342,503,584343,920,358332,333,742333,908,056284,247,342273,973,135275,777,597279,413,654273,405,246263,645,53700000000
       Property Plant Equipment 
92,041,373
98,414,941
110,080,444
144,548,925
146,727,109
153,064,068
178,946,452
196,344,391
236,596,734
246,745,355
250,306,223
249,675,843
247,168,701
245,813,809
245,774,713
243,548,848
241,458,567
239,777,373
235,569,953
232,943,659
232,039,226
232,374,268
231,031,534
218,467,958
216,736,413
215,369,032
213,680,733
211,774,861
211,774,861213,680,733215,369,032216,736,413218,467,958231,031,534232,374,268232,039,226232,943,659235,569,953239,777,373241,458,567243,548,848245,774,713245,813,809247,168,701249,675,843250,306,223246,745,355236,596,734196,344,391178,946,452153,064,068146,727,109144,548,925110,080,44498,414,94192,041,373
       Goodwill 
0
0
2,814,539
0
0
0
0
0
0
0
0
0
0
0
3,984,628
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,121
3,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,696,1213,984,628000000000002,814,53900
       Long Term Investments 
3,272,917
3,216,827
514,370
6,991,400
6,867,943
6,716,926
6,536,399
6,965,930
6,377,353
5,846,069
5,346,858
3,803,999
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,803,9995,346,8585,846,0696,377,3536,965,9306,536,3996,716,9266,867,9436,991,400514,3703,216,8273,272,917
       Intangible Assets 
17,255,898
17,249,089
23,158,644
17,505,415
17,046,718
16,574,755
15,987,189
17,413,857
16,199,863
15,553,977
16,621,677
15,675,917
15,626,475
14,732,300
53,652,328
51,998,715
51,319,746
52,312,636
51,588,907
89,123,225
88,581,339
87,510,760
86,501,176
179,946,306
176,251,798
174,512,773
171,050,311
169,172,907
169,172,907171,050,311174,512,773176,251,798179,946,30686,501,17687,510,76088,581,33989,123,22551,588,90752,312,63651,319,74651,998,71553,652,32814,732,30015,626,47515,675,91716,621,67715,553,97716,199,86317,413,85715,987,18916,574,75517,046,71817,505,41523,158,64417,249,08917,255,898
       Long-term Assets Other 
0
0
0
0
0
0
0
0
307,326
0
790,687
0
0
0
0
-1
0
0
0
1
1
1
-1
10,277
-1
0
0
0
000-110,277-1111000-10000790,6870307,32600000000
> Total Liabilities 
225,567,335
199,955,236
226,430,763
152,862,300
161,486,550
162,727,251
201,242,329
193,914,931
219,193,797
217,934,013
227,401,595
224,675,238
207,305,029
294,292,015
341,545,029
307,706,406
315,581,782
328,659,932
336,263,831
354,327,079
378,182,303
371,879,580
393,374,348
375,969,361
430,741,522
370,002,385
391,043,649
366,258,951
366,258,951391,043,649370,002,385430,741,522375,969,361393,374,348371,879,580378,182,303354,327,079336,263,831328,659,932315,581,782307,706,406341,545,029294,292,015207,305,029224,675,238227,401,595217,934,013219,193,797193,914,931201,242,329162,727,251161,486,550152,862,300226,430,763199,955,236225,567,335
   > Total Current Liabilities 
216,310,247
179,848,035
199,044,119
116,196,775
123,558,392
118,450,156
141,990,802
129,736,933
128,127,057
127,417,337
138,141,621
139,214,472
122,230,130
132,344,156
148,861,155
122,871,383
132,711,626
148,275,533
158,182,540
155,952,639
182,347,121
256,767,333
280,565,777
277,482,941
255,309,342
199,086,146
225,557,455
201,083,021
201,083,021225,557,455199,086,146255,309,342277,482,941280,565,777256,767,333182,347,121155,952,639158,182,540148,275,533132,711,626122,871,383148,861,155132,344,156122,230,130139,214,472138,141,621127,417,337128,127,057129,736,933141,990,802118,450,156123,558,392116,196,775199,044,119179,848,035216,310,247
       Short-term Debt 
52,372,061
54,352,472
50,970,566
66,287,894
57,050,161
61,519,059
416,670
2,709,260
22,817,136
22,534,028
20,118,305
25,791,437
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000025,791,43720,118,30522,534,02822,817,1362,709,260416,67061,519,05957,050,16166,287,89450,970,56654,352,47252,372,061
       Short Long Term Debt 
52,372,061
54,352,472
50,970,566
66,287,894
57,050,161
61,519,059
416,670
2,709,260
22,817,136
22,534,028
20,118,305
25,791,437
21,727,197
24,779,137
20,037,340
20,268,525
22,438,553
23,238,716
23,763,137
25,779,855
27,300,081
112,902,105
105,770,102
112,914,382
106,966,007
42,159,476
43,451,758
50,610,858
50,610,85843,451,75842,159,476106,966,007112,914,382105,770,102112,902,10527,300,08125,779,85523,763,13723,238,71622,438,55320,268,52520,037,34024,779,13721,727,19725,791,43720,118,30522,534,02822,817,1362,709,260416,67061,519,05957,050,16166,287,89450,970,56654,352,47252,372,061
       Accounts payable 
42,639,655
40,360,978
60,600,005
42,172,027
47,428,005
48,759,849
66,817,905
50,805,204
58,461,372
56,155,579
61,365,656
57,203,820
52,160,762
60,099,268
72,848,040
48,520,707
51,809,754
70,976,735
74,806,781
61,515,461
85,911,019
83,109,921
102,464,349
90,316,254
73,576,449
93,696,632
111,394,946
69,419,197
69,419,197111,394,94693,696,63273,576,44990,316,254102,464,34983,109,92185,911,01961,515,46174,806,78170,976,73551,809,75448,520,70772,848,04060,099,26852,160,76257,203,82061,365,65656,155,57958,461,37250,805,20466,817,90548,759,84947,428,00542,172,02760,600,00540,360,97842,639,655
       Other Current Liabilities 
121,298,531
95,134,585
102,473,548
35,136,854
46,480,226
39,491,926
47,305,000
46,339,167
5,799,666
8,015,890
14,049,452
53,881,383
46,578,935
43,778,060
53,043,331
51,982,180
55,565,641
51,021,726
56,740,842
65,256,955
64,056,688
46,609,627
64,519,715
67,572,658
9,829,321
53,604,814
19,227,626
17,890,906
17,890,90619,227,62653,604,8149,829,32167,572,65864,519,71546,609,62764,056,68865,256,95556,740,84251,021,72655,565,64151,982,18053,043,33143,778,06046,578,93553,881,38314,049,4528,015,8905,799,66646,339,16747,305,00039,491,92646,480,22635,136,854102,473,54895,134,585121,298,531
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
91,066,740
90,516,676
89,259,974
85,460,766
85,074,899
161,947,859
192,683,873
184,835,023
182,870,156
180,384,399
178,081,290
198,374,440
195,835,182
115,112,247
112,808,571
98,486,420
175,432,180
170,916,239
165,486,194
165,175,929
165,175,929165,486,194170,916,239175,432,18098,486,420112,808,571115,112,247195,835,182198,374,440178,081,290180,384,399182,870,156184,835,023192,683,873161,947,85985,074,89985,460,76689,259,97490,516,67691,066,74000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
308,319
536,689
794,480
889,227
869,739
927,296
1,494,603
1,335,057
995,671
951,170
760,122
756,871
1,280,985
1,180,409
1,244,596
1,127,506
1,619,421
2,048,708
1,858,952
1,896,785
1,896,7851,858,9522,048,7081,619,4211,127,5061,244,5961,180,4091,280,985756,871760,122951,170995,6711,335,0571,494,603927,296869,739889,227794,480536,689308,31900000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
1,593,127
1,628,675
1,664,224
1,881,795
1,929,200
1,976,606
1,671,434
1,884,361
1,963,998
2,018,278
2,085,237
1,763,471
1,830,029
0
4,550,995
3,636,309
5,918,496
6,507,469
6,873,608
7,295,524
7,295,5246,873,6086,507,4695,918,4963,636,3094,550,99501,830,0291,763,4712,085,2372,018,2781,963,9981,884,3611,671,4341,976,6061,929,2001,881,7951,664,2241,628,6751,593,12700000000
> Total Stockholder Equity
196,179,854
196,872,241
199,898,921
249,653,982
244,347,230
247,401,150
252,186,698
256,102,642
262,464,704
272,605,102
280,465,566
282,953,676
287,141,702
333,988,980
341,628,342
339,909,910
354,633,343
353,025,045
470,988,944
473,863,494
478,734,805
494,192,511
517,888,643
515,917,389
521,320,300
533,077,721
546,050,345
548,749,645
548,749,645546,050,345533,077,721521,320,300515,917,389517,888,643494,192,511478,734,805473,863,494470,988,944353,025,045354,633,343339,909,910341,628,342333,988,980287,141,702282,953,676280,465,566272,605,102262,464,704256,102,642252,186,698247,401,150244,347,230249,653,982199,898,921196,872,241196,179,854
   Common Stock
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
22,100,000
23,810,000
23,810,000
23,810,000
26,060,000
26,060,000
34,345,000
34,345,000
34,345,000
34,345,000
34,345,000
34,345,000
0
34,345,000
0
0
0034,345,000034,345,00034,345,00034,345,00034,345,00034,345,00034,345,00026,060,00026,060,00023,810,00023,810,00023,810,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,00022,100,000
   Retained Earnings 
181,902,686
182,583,762
185,605,257
235,374,508
235,058,550
238,112,205
242,908,045
246,822,400
246,262,827
256,403,749
264,263,565
273,669,372
277,799,347
284,230,780
291,865,563
295,815,768
311,152,604
308,106,151
328,671,888
334,827,105
339,421,697
354,519,532
376,472,277
376,179,305
380,944,690
392,262,984
404,199,342
406,936,348
406,936,348404,199,342392,262,984380,944,690376,179,305376,472,277354,519,532339,421,697334,827,105328,671,888308,106,151311,152,604295,815,768291,865,563284,230,780277,799,347273,669,372264,263,565256,403,749246,262,827246,822,400242,908,045238,112,205235,058,550235,374,508185,605,257182,583,762181,902,686
   Accumulated Other Comprehensive Income 0000000000000000000000000000
   Capital Surplus 0000000000000000000000000000
   Treasury Stock000000000000000000000-15,292,560-15,292,560-15,292,560-10,293,104-10,293,104-10,293,104-10,293,104



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue859,625,586
Cost of Revenue-506,195,732
Gross Profit353,429,854353,429,854
 
Operating Income (+$)
Gross Profit353,429,854
Operating Expense-791,358,565
Operating Income68,267,021-437,928,712
 
Operating Expense (+$)
Research Development47,286,087
Selling General Administrative92,057,012
Selling And Marketing Expenses0
Operating Expense791,358,565139,343,099
 
Net Interest Income (+$)
Interest Income871,770
Interest Expense-9,549,147
Other Finance Cost-0
Net Interest Income-8,677,377
 
Pretax Income (+$)
Operating Income68,267,021
Net Interest Income-8,677,377
Other Non-Operating Income Expenses0
Income Before Tax (EBT)56,305,54168,267,021
EBIT - interestExpense = -9,549,147
40,202,798
49,751,945
Interest Expense9,549,147
Earnings Before Interest and Taxes (EBIT)065,854,688
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax56,305,541
Tax Provision-16,092,403
Net Income From Continuing Ops40,213,13840,213,138
Net Income40,202,798
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net08,677,377
 

Technical Analysis of Boryung
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Boryung. The general trend of Boryung is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Boryung's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Boryung Pharm.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 11,700 < 13,750.

The bearish price targets are: 10,870 > 10,800 > 10,800.

Tweet this
Boryung Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Boryung Pharm. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Boryung Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Boryung Pharm. The current macd is -431.12145017.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Boryung price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Boryung. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Boryung price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Boryung Pharm Daily Moving Average Convergence/Divergence (MACD) ChartBoryung Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Boryung Pharm. The current adx is 39.02.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Boryung shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Boryung Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Boryung Pharm. The current sar is 11,250.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Boryung Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Boryung Pharm. The current rsi is 34.07. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Boryung Pharm Daily Relative Strength Index (RSI) ChartBoryung Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Boryung Pharm. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Boryung price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Boryung Pharm Daily Stochastic Oscillator ChartBoryung Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Boryung Pharm. The current cci is -72.06043222.

Boryung Pharm Daily Commodity Channel Index (CCI) ChartBoryung Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Boryung Pharm. The current cmo is -36.27605199.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Boryung Pharm Daily Chande Momentum Oscillator (CMO) ChartBoryung Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Boryung Pharm. The current willr is -85.98130841.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Boryung Pharm Daily Williams %R ChartBoryung Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Boryung Pharm.

Boryung Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Boryung Pharm. The current atr is 356.84.

Boryung Pharm Daily Average True Range (ATR) ChartBoryung Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Boryung Pharm. The current obv is 21,256,698.

Boryung Pharm Daily On-Balance Volume (OBV) ChartBoryung Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Boryung Pharm. The current mfi is 20.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Boryung Pharm Daily Money Flow Index (MFI) ChartBoryung Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Boryung Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Boryung Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Boryung Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.069
Ma 20Greater thanMa 5011,625.000
Ma 50Greater thanMa 10012,218.800
Ma 100Greater thanMa 20011,832.400
OpenGreater thanClose10,880.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Boryung with someone you think should read this too:
  • Are you bullish or bearish on Boryung? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Boryung? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Boryung Pharm

I send you an email if I find something interesting about Boryung Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Boryung Pharm.

Receive notifications about Boryung Pharm in your mailbox!